High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma
- 1 March 2004
- journal article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 33 (6), 635-638
- https://doi.org/10.1038/sj.bmt.1704392
Abstract
Primary systemic anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL) has a poor prognosis. This study sought to determine if high-dose therapy and ASCT results in long-term disease-free survival (DFS) in patients with recurrent, chemotherapy-sensitive ALK-negative ALCL. All patients with non-Hodgkin's lymphoma (NHL) who underwent ASCT at Wake Forest University and Upstate Medical University from 1 January 1990 to 12 December 2002 were reviewed to determine if they had T-, B- or null-cell NHL that was CD30+/CD15-/ALK negative. In all, 16 patients were thus identified as having ALK-negative ALCL. All 16 patients underwent ASCT at the time of first relapse and form the basis of this report. Median age of the 16 patients was 51 years. There were 11 males and five females. International prognostic index scores in 12 patients at the time of relapse were: low 3, LI 6 and HI 3. Of 15 patients, 13 relapsed after ASCT; one patient was lost to follow-up. Median progression-free survival for the 15 patients was 12 weeks (3–212+ weeks). Of 15 patients, 10 have died; nine of recurrent disease. Median overall survival for the 15 evaluable patients was 72 weeks. In our experience, high-dose therapy and ASCT does not produce long-term DFS in patients with recurrent chemotherapy-sensitive ALK-negative ALCL.Keywords
This publication has 14 references indexed in Scilit:
- Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphomaBlood, 2002
- Impact of High-Dose Chemotherapy on Peripheral T-Cell LymphomasJournal of Clinical Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Anaplastic large cell lymphoma: pathological, molecular and clinical featuresBritish Journal of Haematology, 2001
- Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell LineageThe American Journal of Pathology, 2001
- High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomasBone Marrow Transplantation, 2001
- Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trialBritish Journal of Haematology, 2000
- Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)Bone Marrow Transplantation, 1999
- Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.Journal of Clinical Oncology, 1997
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993